About: Pharmacovigilance in Patients with Diabetes: A Data-Driven Analysis Identifying Specific RAS Antagonists with Adverse Pulmonary Safety Profiles That Have Implications for COVID-19 Morbidity and Mortality

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacovigilance in Patients with Diabetes: A Data-Driven Analysis Identifying Specific RAS Antagonists with Adverse Pulmonary Safety Profiles That Have Implications for COVID-19 Morbidity and Mortality Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pharmacovigilance in Patients with Diabetes: A Data-Driven Analysis Identifying Specific RAS Antagonists with Adverse Pulmonary Safety Profiles That Have Implications for COVID-19 Morbidity and Mortality
Creator	Fellow, Postdoctoral, Professor, Distinguished, D Douraki, Jaberi Eg, Stafford Fellow, Postdoctoral Gj, Wyckoff Jaberi-Douraki, Majid Kawakami, Jessica Research, Postdoctoral Riviere, Jim Stafford, Emma Wyckoff, Gerald Xu, Xuan
Source	Elsevier; Medline; PMC
abstract	ABSTRACT OBJECTIVES Current demographic information from China reports that 10-19% of patients hospitalized with COVID-19 were diabetic. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) are considered first-line agents in diabetics due to their nephroprotective effects but administration of these drugs leads to upregulation of angiotensin-converting-enzyme-2 (ACE2), responsible for viral entry of severe-acute-respiratory-distress-syndrome, coronavirus-2 (SARS-CoV-2). Data is lacking to determine what pulmonary effects ACEIs/ARBs may have in patients with diabetes, which could be relevant in the management of patients infected with SARS-CoV-2. In this study, the aim was to assess the prevalence of pulmonary adverse drug effects (ADEs) in diabetic patients taking ACEI or ARBs to help provide guidance as to how these medications could affect outcomes in acute respiratory illness, such as SARS-CoV-2 infection. METHODS 1DATA, a unique data platform resulting from collaboration across veterinary and human healthcare, utilized an intelligent medicine recommender system (1DrugAssist) developed using several national and international databases, to evaluate all ADEs reported to the FDA for patients with diabetes taking ACEIs or ARBs. RESULTS Mining of this data elucidated the proportion of a cluster of pulmonary ADEs associated with specific medications in these classes, which may aid healthcare professionals in understanding how these medications could worsen or predispose patients with diabetes to infections affecting the respiratory system specifically, COVID-19. Based on this data mining, Captopril was found to have a statistically significantly higher incidence of pulmonary ADEs compared to other ACEIs (P = 0.005) as well as ARBs (P = 0.012), though other specific drugs also had important pulmonary ADEs associated with their use. CONCLUSION These analyses suggest that pharmacists and clinicians will need to consider specific medication’s adverse event profile, particularly captopril, and how this profile may affect infections and other acute disease states that alter pulmonary function, such as COVID-19.
has issue date	2020-06-01(xsd:dateTime)
bibo:doi	10.1016/j.japh.2020.05.018
bibo:pmid	32561317
has license	els-covid
sha1sum (hex)	2cfbd9106c09a8ff151de338a0ec23a6677c14ad
schema:url	https://doi.org/10.1016/j.japh.2020.05.018
resource representing a document's title	Pharmacovigilance in Patients with Diabetes: A Data-Driven Analysis Identifying Specific RAS Antagonists with Adverse Pulmonary Safety Profiles That Have Implications for COVID-19 Morbidity and Mortality
has PubMed Central identifier	PMC7262497
has PubMed identifier	32561317
schema:publication	J Am Pharm Assoc (2003)
resource representing a document's body	covid:2cfbd9106c09a8ff151de338a0ec23a6677c14ad#body_text
is schema:about of	named entity 'Diabetes' named entity 'Safety' named entity 'COVID-19' named entity 'Identifying' named entity 'Profiles' named entity 'Identifying' named entity 'RAS' named entity 'Affiliation' named entity 'Pulmonary' named entity 'Pharmacovigilance' named entity 'Diabetes' named entity 'confidence interval' named entity 'comorbid conditions' named entity 'statistically significant' named entity 'lung tissue' named entity 'enzyme' named entity 'receptor' named entity 'diabetes' named entity 'pathophysiologic' named entity 'SARS-CoV-2' named entity 'infection' named entity 'COVID-19' named entity 'ARBs' named entity 'ACE2' named entity 'acute kidney injury' named entity 'MedDRA' named entity 'ARBs' named entity 'cough' named entity 'SARS-CoV-2' named entity 'Captopril' named entity 'FDA' named entity 'morbidity' named entity 'dyspnea' named entity 'COVID' named entity 'China' named entity 'first-line' named entity 'angiotensin-converting enzyme inhibitors' named entity 'demographic information' named entity 'Captopril' named entity 'adverse event' named entity 'diabetic patients' named entity 'hyperglycemia' named entity 'coronavirus' named entity 'Kansas State University' named entity 'ARBs' named entity 'virus entry' named entity 'SARS' named entity 'Captopril' named entity 'kidneys' named entity 'prodrug' named entity 'COVID' named entity 'ARBs' named entity 'diabetes' named entity 'acute respiratory distress syndrome' named entity 'ARBs' named entity 'diabetes 2' named entity 'ACE2' named entity 'ACEi' named entity 'diabetes' named entity 'animal models' named entity 'COVID' named entity 'viral entry' named entity 'dyspnea' named entity 'angiotensin' named entity 'COVID-19 outbreak' named entity 'diabetes' named entity 'ARBs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software